Showing 901-910 of 989 results for "".
- Allergan CEO Calls for Consensus on Medical Aesthetic Treatment in Minorshttps://modernaesthetics.com/news/allergan-ceo-calls-for-consensus-on-medical-aesthetic-treatment-in-minors/2472213/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- ASDS: Seven of 10 Consumers Considering Nips or Tuckshttps://modernaesthetics.com/news/asds-seven-of-10-consumers-considering-plastic-surgery/2472214/Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASD
- USA, Brazil Take the Lead for Most Plastic Surgery Procedureshttps://modernaesthetics.com/news/usa-brazil-take-the-lead-for-most-plastic-surgery-procedures/2472215/Plastic surgery is on the rise across the globe, according to new statistics from The International Society of Aesthetic Plastic Surgery (ISAPS). There was an overall increase of 9 percent in surgical and non-surgical cosmetic procedures in 2016.
- Sculpture OK'd for Back, Inner and Outer Thighshttps://modernaesthetics.com/news/sculpsure-oked-for-back-inner-and-outer-thighs/2472220/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdom
- Sciton Launches diVa® Center of Excellence Programhttps://modernaesthetics.com/news/sciton-launches-diva-center-of-excellence-program/2472230/Sciton, Inc.’s new diVa® Center of Excellence Program will spotlight urogynecologists, urologists, OB/GYN's and gynecologists who are dedicated to creating an optimal Treatment Experience for women. The Centers will review data and outcome
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers for “Laugh Lines”https://modernaesthetics.com/news/fda-approves-restylane-refyne-and-restylane-defyne-dermal-fillers-for-laugh-lines/2472303/The FDA has approved two new Galderma products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkles and folds and Restylane®
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Richard Goldfarb, MD, FACShttps://modernaesthetics.com/profiles/richard-goldfarb-md-facs/j5ea22/
- Richard Goldfarb, MD, FACShttps://modernaesthetics.com/profiles/richard-goldfarb-md-facs/LkkB2l/